Spiro<4.4>nonane-1,6-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Spiro<4.4>nonane-1,6-diol
• 英文别名: spiro[4.4]nonane-4,9-diol
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: ACIVJWAOSTYYEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-methoxytrifluoromethylphenylacetyl chloride 、 Spiro<4.4>nonane-1,6-diol 在 4-二甲氨基吡啶 作用下， 生成 (R)-3,3,3-Trifluoro-2-methoxy-2-phenyl-propionic acid 6-((R)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionyloxy)-spiro[4.4]non-1-yl ester
  参考文献：
  名称：

  1 h核磁共振测定螺环醇的绝对构型和对映体纯度

  摘要：

  螺[4.4]壬烷和2,2'-螺双茚满的一些羟基酮和二醇的绝对构型和对映体纯度可通过使用MTPA衍生物和镧系元素转移试剂同时测定。

  DOI：

  10.1016/s0040-4039(01)81690-7
• 作为产物：
  描述：

  (+)-(5R)-spiro<4.4>nonanae-1,6-dione 在 bis(cyclohexanyl)borane 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以18%的产率得到Spiro<4.4>nonane-1,6-diol
  参考文献：
  名称：

  1 h核磁共振测定螺环醇的绝对构型和对映体纯度

  摘要：

  螺[4.4]壬烷和2,2'-螺双茚满的一些羟基酮和二醇的绝对构型和对映体纯度可通过使用MTPA衍生物和镧系元素转移试剂同时测定。

  DOI：

  10.1016/s0040-4039(01)81690-7

文献信息

• Enantioselective Phosphoramidite Compounds and Catalysts
  申请人：Hartwig F. John

  公开号：US20070259774A1

  公开（公告）日：2007-11-08

  This invention relates to phosphoramidite compounds and catalyst complexes which can be used to provide enantioselective reactions including hydroamination reactions, etherification reactions and conjugate addition reactions and allylic substitution reactions, among others. In a first aspect, the present invention is directed to phosphoramidite and related compounds according to general structure (I), where Z is absent or is a group containing O, N or S, preferably O; R 1 and R 2 are independently an optionally substituted C 1-12 alkyl group, an optionally substituted (CH 2 ) n -aromatic group or (CH 2 ) n -heteroaromatic group, or are linked together to form an optionally substituted aliphatic or (CH 2 ) n -aromatic dianion of a diol, diamine, dithiol, aminoalcohol, aminohiolate or a alcoholthiol group; R 3′ and R 3 are each independently H, an optionally substituted C 1 -C 12 alkyl group or an optionally substituted (CH 2 ) n -aromatic group with the proviso that R 3′ and R 3 are not both H, or together R 3′ and R 3 form an optionally substituted C 5 -C 15 saturated or unsaturated carbocyclic ring; R 4 is H, an optionally substituted C 1 -C 12 alkyl group or an optionally substituted (CH 2 ) n -aromatic group; R 5 is absent, H, an optionally substituted C 1 -C 12 alkyl group or an optionally substituted (CH 2 ) n -aromatic or (CH 2 ) n -heteroaromatic group; R a and R a′ are each independently H or a C 1 -C 3 alkyl group, or R a and R a′ together with the carbon to which they are attached form a optionally substituted C 5 -C 15 saturated or unsaturated carbocyclic or heterocyclic ring, or an aromatic or heteroaromatic ring; R 6 and R 7 are each independently H, an optionally substituted C 1 -C 12 alkyl group or an optionally substituted (CH 2 ) n -aromatic group, with the proviso that R 5 , R 6 and R 7 cannot simultaneously be H, and when R a and R a′ , together with the carbon to which they are attached, form a carbocyclic ring, heterocyclic ring or an aromatic or heteroaromatic ring, R 5 is absent or is preferably H; R 6 and R 7 are preferably H or CH 3 ; and each n is independently 0, 1, 2, 3, 4, 5 or 6 and wherein at least one of the carbon atoms attached to the nitrogen of the phosphoramidite group is a chiral center.

  本发明涉及磷酰胺类化合物和催化剂复合物，可用于提供对映选择性反应，包括羟胺化反应、醚化反应和共轭加成反应以及联烯取代反应等。在第一个方面，本发明涉及磷酰胺和相关化合物，其一般结构如下（I），其中Z不存在或是包含O、N或S的基团，优选为O；R1和R2分别为可选取代的C1-12烷基、可选取代的（CH2）n-芳基或（ ）n-杂芳基，或相互连接形成可选取代的脂肪族或（ ）n-芳香基的二阴离子的二元醇、二胺、二硫醇、氨基醇、氨基硫醇或醇硫基基团；R3'和R3各自独立地为H、可选取代的C1-C12烷基或可选取代的（ ）n-芳基，但须满足R3'和R3不能同时为H，或者R3'和R3共同形成可选取代的C5-C15饱和或不饱和的碳环；R4为H、可选取代的C1-C12烷基或可选取代的（ ）n-芳基；R5不存在、为H、可选取代的C1-C12烷基或可选取代的（ ）n-芳基或（ ）n-杂芳基；Ra和Ra'各自独立地为H或C1-C3烷基，或者Ra和Ra'与它们附着的碳共同形成可选取代的C5-C15饱和或不饱和的碳环或杂环，或芳香或杂芳环；R6和R7各自独立地为H、可选取代的C1-C12烷基或可选取代的（ ）n-芳基，但须满足R5、R6和R7不能同时为H，且当Ra和Ra'与它们附着的碳共同形成碳环、杂环或芳香或杂芳环时，R5不存在或优选为H；R6和R7优选为H或CH3；每个n独立地为0、1、2、3、4、5或6，其中至少有一个连接到磷酰胺基团氮上的碳原子是手性中心。
• SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20150274705A1

  公开（公告）日：2015-10-01

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了一种新型的杂环芳香化合物，其药物可接受的盐和制剂，可用于预防、治疗或减轻蛋白质介导的疾病的严重程度。该发明还提供了包含这些化合物的药学可接受的组合物和使用这些组合物治疗蛋白激酶介导的疾病的方法。
• PLATINUM COMPLEX AND MEDICAL COMPOUND CONTAINING SAME
  申请人：Unitech Co., Ltd

  公开号：EP2325163A1

  公开（公告）日：2011-05-25

  A new platinum complex which has strong antitumor activity and has effect with smaller doses and a pharmaceutical composition containing the same are provided. A spiro[4,4]nonme-1,6-diamineplatinum(II) complex which is represented by a following general formula (A). (In the formula, X and Y are same or different, and X and Y represent halogen atoms respectively, or X and Y cooperatively represent a divalent residue which is described by a formula (Z) .) The platinum complex has a strong antitumor activity and is efficacious as a therapeutic agent for malignant tumors.

  本研究提供了一种抗肿瘤活性强、剂量较小的新型铂络合物和含有该铂络合物的药物组合物。一种螺[4,4]壬-1,6-二氨铂(II)络合物，由以下通式（A）表示。(式中，X 和 Y 相同或不同，X 和 Y 分别代表卤素原子，或 X 和 Y 共同代表二价残基，二价残基用式（Z）表示）。铂络合物具有很强的抗肿瘤活性，可作为恶性肿瘤的有效治疗剂。
• PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Arai Hisae

  公开号：US20110152555A1

  公开（公告）日：2011-06-23

  A new platinum complex which has strong antitumor activity and has effect with smaller doses and a pharmaceutical composition containing the same are provided. A spiro[4,4]nonane-1,6-diamineplatinum(II) complex which is represented by a following general formula (A). (In the formula, X and Y are same or different, and X and Y represent halogen atoms respectively, or X and Y cooperatively represent a divalent residue which is described by a formula (Z).) The platinum complex has a strong antitumor activity and is efficacious as a therapeutic agent for malignant tumors.
• US7732365B2
  申请人：——

  公开号：US7732365B2

  公开（公告）日：2010-06-08